Ascent Group, LLC Vertex Pharmaceuticals Inc Transaction History

Ascent Group, LLC

$1.29 Billion
Q3 2024

A detailed history of Ascent Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ascent Group, LLC holds 10,796 shares of VRTX stock, worth $4.43 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

10,796

Previous 9,033 19.52%

Holding current value

$4.43 Million

Previous $4.23 Million 18.62%

% of portfolio

0.39%

Previous 0.35%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $810,980 - $891,690	1,763 Added 19.52%	10,796 $5.02 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $163,408 - $201,980	416 Added 4.83%	9,033 $4.23 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $1.94 Million - $2.12 Million	-4,759 Reduced 35.58%	8,617 $3.6 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $552,916 - $662,016	1,612 Added 13.7%	13,376 $5.44 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $12,850 - $13,773	38 Added 0.32%	11,764 $4.09 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $1.02 Million - $1.14 Million	3,239 Added 38.16%	11,726 $4.13 Million
Q1 2023 May 10, 2023	BUY	$283.23 - $323.1 $997,536 - $1.14 Million	3,522 Added 70.94%	8,487 $2.67 Million
Q4 2022 Feb 16, 2023	BUY	$285.76 - $321.48 $191,744 - $215,713	671 Added 15.63%	4,965 $1.43 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $872,422 - $973,418	3,186 Added 287.55%	4,294 $1.34 Million
Q2 2022 Aug 05, 2022	BUY	$234.96 - $292.55 $260,335 - $324,145	1,108 New	1,108 $311,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ascent Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ascent Group, LLC with notifications on news.

Account